633 related articles for article (PubMed ID: 29648650)
1. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects.
Sliz E; Sebert S; Würtz P; Kangas AJ; Soininen P; Lehtimäki T; Kähönen M; Viikari J; Männikkö M; Ala-Korpela M; Raitakari OT; Kettunen J
Hum Mol Genet; 2018 Jun; 27(12):2214-2223. PubMed ID: 29648650
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals.
Lin YC; Chang PF; Chang MH; Ni YH
Am J Clin Nutr; 2014 Apr; 99(4):869-74. PubMed ID: 24477042
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy.
Di Costanzo A; Belardinilli F; Bailetti D; Sponziello M; D'Erasmo L; Polimeni L; Baratta F; Pastori D; Ceci F; Montali A; Girelli G; De Masi B; Angeloni A; Giannini G; Del Ben M; Angelico F; Arca M
Sci Rep; 2018 Feb; 8(1):3702. PubMed ID: 29487372
[TBL] [Abstract][Full Text] [Related]
4. Relevance of
Elmansoury N; Megahed AA; Kamal A; El-Nikhely N; Labane M; Abdelmageed M; Daly AK; Wahid A
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674389
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort
Anstee QM; Darlay R; Cockell S; Meroni M; Govaere O; Tiniakos D; Burt AD; Bedossa P; Palmer J; Liu YL; Aithal GP; Allison M; Yki-Järvinen H; Vacca M; Dufour JF; Invernizzi P; Prati D; Ekstedt M; Kechagias S; Francque S; Petta S; Bugianesi E; Clement K; Ratziu V; Schattenberg JM; Valenti L; Day CP; Cordell HJ; Daly AK;
J Hepatol; 2020 Sep; 73(3):505-515. PubMed ID: 32298765
[TBL] [Abstract][Full Text] [Related]
6. Analysis of genotyping for predicting liver injury marker, procollagen III in persons at risk of non-alcoholic fatty liver disease.
Grove JI; Thiagarajan P; Astbury S; Harris R; Delahooke T; Guha IN; Aithal GP
Liver Int; 2018 Oct; 38(10):1832-1838. PubMed ID: 29493856
[TBL] [Abstract][Full Text] [Related]
7. Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents.
Zusi C; Mantovani A; Olivieri F; Morandi A; Corradi M; Miraglia Del Giudice E; Dauriz M; Valenti L; Byrne CD; Targher G; Maffeis C
Dig Liver Dis; 2019 Nov; 51(11):1586-1592. PubMed ID: 31255630
[TBL] [Abstract][Full Text] [Related]
8. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits.
Kitamoto A; Kitamoto T; Nakamura T; Ogawa Y; Yoneda M; Hyogo H; Ochi H; Mizusawa S; Ueno T; Nakao K; Sekine A; Chayama K; Nakajima A; Hotta K
Endocr J; 2014; 61(7):683-9. PubMed ID: 24785259
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
[TBL] [Abstract][Full Text] [Related]
10. Genetic determinants of steatosis and fibrosis progression in paediatric non-alcoholic fatty liver disease.
Hudert CA; Selinski S; Rudolph B; Bläker H; Loddenkemper C; Thielhorn R; Berndt N; Golka K; Cadenas C; Reinders J; Henning S; Bufler P; Jansen PLM; Holzhütter HG; Meierhofer D; Hengstler JG; Wiegand S
Liver Int; 2019 Mar; 39(3):540-556. PubMed ID: 30444569
[TBL] [Abstract][Full Text] [Related]
11. A genetic risk score is associated with hepatic triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity.
León-Mimila P; Vega-Badillo J; Gutiérrez-Vidal R; Villamil-Ramírez H; Villareal-Molina T; Larrieta-Carrasco E; López-Contreras BE; Kauffer LR; Maldonado-Pintado DG; Méndez-Sánchez N; Tovar AR; Hernández-Pando R; Velázquez-Cruz R; Campos-Pérez F; Aguilar-Salinas CA; Canizales-Quinteros S
Exp Mol Pathol; 2015 Apr; 98(2):178-83. PubMed ID: 25597287
[TBL] [Abstract][Full Text] [Related]
12. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
[TBL] [Abstract][Full Text] [Related]
13. Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program.
Serper M; Vujkovic M; Kaplan DE; Carr RM; Lee KM; Shao Q; Miller DR; Reaven PD; Phillips LS; O'Donnell CJ; Meigs JB; Wilson PWF; Vickers-Smith R; Kranzler HR; Justice AC; Gaziano JM; Muralidhar S; Pyarajan S; DuVall SL; Assimes TL; Lee JS; Tsao PS; Rader DJ; Damrauer SM; Lynch JA; Saleheen D; Voight BF; Chang KM;
PLoS One; 2020; 15(8):e0237430. PubMed ID: 32841307
[TBL] [Abstract][Full Text] [Related]
14. Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.
Flores YN; Velázquez-Cruz R; Ramírez P; Bañuelos M; Zhang ZF; Yee HF; Chang SC; Canizales-Quinteros S; Quiterio M; Cabrera-Alvarez G; Patiño N; Salmerón J
Mol Biol Rep; 2016 Dec; 43(12):1359-1369. PubMed ID: 27752939
[TBL] [Abstract][Full Text] [Related]
15. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey.
Hernaez R; McLean J; Lazo M; Brancati FL; Hirschhorn JN; Borecki IB; Harris TB; ; Nguyen T; Kamel IR; Bonekamp S; Eberhardt MS; Clark JM; Kao WH; Speliotes EK
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1183-1190.e2. PubMed ID: 23416328
[TBL] [Abstract][Full Text] [Related]
16. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
[TBL] [Abstract][Full Text] [Related]
17. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
[TBL] [Abstract][Full Text] [Related]
18. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children.
Lin YC; Chang PF; Chang MH; Ni YH
Liver Int; 2018 Jul; 38(7):1300-1307. PubMed ID: 29314568
[TBL] [Abstract][Full Text] [Related]
19. Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene.
Tan HL; Zain SM; Mohamed R; Rampal S; Chin KF; Basu RC; Cheah PL; Mahadeva S; Mohamed Z
J Gastroenterol; 2014 Jun; 49(6):1056-64. PubMed ID: 23800943
[TBL] [Abstract][Full Text] [Related]
20. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W
J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
